Pharmacogenetics and pharmacogenomics for rheumatoid arthritis responsiveness to methotrexate treatment: the 2013 update. (March 2014)

• Record Type: Journal Article
• Authors: Zhu, Hong; Deng, Fei-Yan; Mo, Xing-Bo; Qiu, Ying-Hua; Lei, Shu-Feng
• Is Part Of: Pharmacogenomics. Volume 15:Number 4(2014)
• Page Start: 551
• Page End: 566
• Publication Date: 2014-03
• Subjects: methotrexate -- pharmacogenetics -- pharmacogenomics -- rheumatoid arthritis; Pharmacogenomics -- Periodicals; 615.1
• DOI: 10.2217/pgs.14.25
• Languages: English
• ISSNs: 1462-2416

Abstract

Rheumatoid arthritis (RA) is a complex, systemic autoimmune disease characterized by chronic inflammation of multiple peripheral joints, which leads to serious destruction of cartilage and bone, progressive deformity and severe disability. Methotrexate (MTX) is one of the first-line drugs commonly used in RA therapy owing to its excellent long-term efficacy and cheapness. However, the efficacy and toxicity of MTX treatment have significant interpatient variability. Genetic factors contribute to this variability. In this review, we have summarized and updated the progress of RA response to MTX treatment since 2009 by focusing on the fields of pharmacogenetics and pharmacogenomics. Identification of genetic factors involved in MTX treatment response will increase the understanding of RA pathology and the development of new personalized treatments.